OBJECTIVE: To estimate the effect of ultrasound screening on stage at detection and long-term disease-specific survival of at-risk women with epithelial ovarian cancer. METHODS: Eligibility included all asymptomatic women 50 years of age or older and women 25 years of age or older with a documented family history of ovarian cancer. From 1987 to 2017, 46,101 women received annual ultrasound screening in a prospective cohort trial. Women with a persisting abnormal screen underwent tumor morphology indexing, serum biomarker analysis, and surgery. RESULTS: Seventy-one invasive epithelial ovarian cancers and 17 epithelial ovarian tumors of low malignant potential were detected. No women with a low malignant potential tumor experienced recurrent disease. Stage distribution for screen-detected invasive epithelial ovarian cancers was stage I-30 (42%), stage II-15 (21%), stage III-26 (37%), and stage IV-0 (0%). Follow-up varied from 9.2 months to 27 years (mean 7.9 years). Disease-specific survival at 5, 10, and 20 years for women with invasive epithelial ovarian cancer detected by screening was 86±4%, 68±7%, and 65±7%, respectively, vs 45±2%, 31±2%, and 19±3%, respectively, for unscreened women with clinically detected ovarian cancer from the same geographic area who were treated at the same institution by the same treatment protocols (P<.001). Twenty-seven percent of screen-detected malignancies were type I and 73% were type II. The disease-specific survival of women with type I and type II screen-detected tumors was significantly higher than that of women with clinically detected type I and type II tumors and was related directly to earlier stage at detection. CONCLUSION: Annual ultrasound screening of at-risk asymptomatic women was associated with lower stage at detection and increased 5-, 10-, and 20-year disease-specific survival of women with both type I and type II epithelial ovarian cancer. CLINICAL TRIAL REGISTRATION: OnCore Clinical Trials Management System, NCI-2013-01954.
OBJECTIVE: To estimate the effect of ultrasound screening on stage at detection and long-term disease-specific survival of at-risk women with epithelial ovarian cancer. METHODS: Eligibility included all asymptomatic women 50 years of age or older and women 25 years of age or older with a documented family history of ovarian cancer. From 1987 to 2017, 46,101 women received annual ultrasound screening in a prospective cohort trial. Women with a persisting abnormal screen underwent tumor morphology indexing, serum biomarker analysis, and surgery. RESULTS: Seventy-one invasive epithelial ovarian cancers and 17 epithelial ovarian tumors of low malignant potential were detected. No women with a low malignant potential tumor experienced recurrent disease. Stage distribution for screen-detected invasive epithelial ovarian cancers was stage I-30 (42%), stage II-15 (21%), stage III-26 (37%), and stage IV-0 (0%). Follow-up varied from 9.2 months to 27 years (mean 7.9 years). Disease-specific survival at 5, 10, and 20 years for women with invasive epithelial ovarian cancer detected by screening was 86±4%, 68±7%, and 65±7%, respectively, vs 45±2%, 31±2%, and 19±3%, respectively, for unscreened women with clinically detected ovarian cancer from the same geographic area who were treated at the same institution by the same treatment protocols (P<.001). Twenty-seven percent of screen-detected malignancies were type I and 73% were type II. The disease-specific survival of women with type I and type II screen-detected tumors was significantly higher than that of women with clinically detected type I and type II tumors and was related directly to earlier stage at detection. CONCLUSION: Annual ultrasound screening of at-risk asymptomatic women was associated with lower stage at detection and increased 5-, 10-, and 20-year disease-specific survival of women with both type I and type II epithelial ovarian cancer. CLINICAL TRIAL REGISTRATION: OnCore Clinical Trials Management System, NCI-2013-01954.
Authors: Brook A Saunders; Iwona Podzielinski; Rachel A Ware; Scott Goodrich; Christopher P DeSimone; Fred R Ueland; Leigh Seamon; Jessalyn Ubellacker; Edward J Pavlik; Richard J Kryscio; John R van Nagell Journal: Gynecol Oncol Date: 2010-06-15 Impact factor: 5.482
Authors: Usha Menon; Aleksandra Gentry-Maharaj; Rachel Hallett; Andy Ryan; Matthew Burnell; Aarti Sharma; Sara Lewis; Susan Davies; Susan Philpott; Alberto Lopes; Keith Godfrey; David Oram; Jonathan Herod; Karin Williamson; Mourad W Seif; Ian Scott; Tim Mould; Robert Woolas; John Murdoch; Stephen Dobbs; Nazar N Amso; Simon Leeson; Derek Cruickshank; Alistair McGuire; Stuart Campbell; Lesley Fallowfield; Naveena Singh; Anne Dawnay; Steven J Skates; Mahesh Parmar; Ian Jacobs Journal: Lancet Oncol Date: 2009-03-11 Impact factor: 41.316
Authors: Susan C Modesitt; Edward J Pavlik; Frederick R Ueland; Paul D DePriest; R J Kryscio; J R van Nagell Journal: Obstet Gynecol Date: 2003-09 Impact factor: 7.661
Authors: H Kobayashi; Y Yamada; T Sado; M Sakata; S Yoshida; R Kawaguchi; S Kanayama; H Shigetomi; S Haruta; Y Tsuji; S Ueda; T Kitanaka Journal: Int J Gynecol Cancer Date: 2007-07-21 Impact factor: 3.437
Authors: John Hoff; Lauren Baldwin; Jason Lefringhouse; Edward Pavlik; Rachel Miller; Christopher DeSimone; Frederick Ueland; Thomas Tucker; Richard Kryscio; J R van Nagell Journal: J Oncol Date: 2014-09-01 Impact factor: 4.375
Authors: Usha Menon; Alistair J McGuire; Maria Raikou; Andy Ryan; Susan K Davies; Matthew Burnell; Aleksandra Gentry-Maharaj; Jatinderpal K Kalsi; Naveena Singh; Nazar N Amso; Derek Cruickshank; Stephen Dobbs; Keith Godfrey; Jonathan Herod; Simon Leeson; Tim Mould; John Murdoch; David Oram; Ian Scott; Mourad W Seif; Karin Williamson; Robert Woolas; Lesley Fallowfield; Stuart Campbell; Steven J Skates; Mahesh Parmar; Ian J Jacobs Journal: Br J Cancer Date: 2017-07-25 Impact factor: 7.640
Authors: Usha Menon; Aleksandra Gentry-Maharaj; Matthew Burnell; Naveena Singh; Andy Ryan; Chloe Karpinskyj; Giulia Carlino; Julie Taylor; Susan K Massingham; Maria Raikou; Jatinderpal K Kalsi; Robert Woolas; Ranjit Manchanda; Rupali Arora; Laura Casey; Anne Dawnay; Stephen Dobbs; Simon Leeson; Tim Mould; Mourad W Seif; Aarti Sharma; Karin Williamson; Yiling Liu; Lesley Fallowfield; Alistair J McGuire; Stuart Campbell; Steven J Skates; Ian J Jacobs; Mahesh Parmar Journal: Lancet Date: 2021-05-12 Impact factor: 79.321
Authors: Robert C Bast; Zhen Lu; Chae Young Han; Karen H Lu; Karen S Anderson; Charles W Drescher; Steven J Skates Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-10-13 Impact factor: 4.254
Authors: Jatinderpal Kalsi; Aleksandra Gentry-Maharaj; Andy Ryan; Naveena Singh; Matthew Burnell; Susan Massingham; Sophia Apostolidou; Aarti Sharma; Karin Williamson; Mourad Seif; Tim Mould; Robert Woolas; Stephen Dobbs; Simon Leeson; Lesley Fallowfield; Steven J Skates; Mahesh Parmar; Stuart Campbell; Ian Jacobs; Alistair McGuire; Usha Menon Journal: Cancers (Basel) Date: 2021-02-18 Impact factor: 6.639
Authors: Edward J Pavlik; Emily Brekke; Justin Gorski; Lauren Baldwin-Branch; Rachel Miller; Christopher P DeSimone; Charles S Dietrich; Holly S Gallion; Frederick Rand Ueland; John R van Nagell Journal: Diagnostics (Basel) Date: 2022-01-06
Authors: Justin W Gorski; Charles S Dietrich; Caeli Davis; Lindsay Erol; Hayley Dietrich; Nicholas J Per; Emily Lenk Ferrell; Anthony B McDowell; McKayla J Riggs; Megan L Hutchcraft; Lauren A Baldwin-Branch; Rachel W Miller; Christopher P DeSimone; Holly H Gallion; Frederick R Ueland; John R van Nagell; Edward J Pavlik Journal: Diagnostics (Basel) Date: 2022-01-07